Overview
Interatrial communication, commonly known as atrial septal defect (ASD), is a congenital heart defect characterized by an abnormal opening in the septum (wall) that separates the two upper chambers (atria) of the heart. This opening allows oxygen-rich blood from the left atrium to mix with oxygen-poor blood in the right atrium, resulting in a left-to-right shunt that increases blood flow to the lungs. There are several types of ASD, including ostium secundum (the most common, located in the central portion of the septum), ostium primum (located in the lower part of the septum, often associated with atrioventricular valve abnormalities), sinus venosus (located near the entry of the superior or inferior vena cava), and coronary sinus defects. Many individuals with small ASDs are asymptomatic in childhood, and the defect may not be detected until adulthood. When symptoms do occur, they can include fatigue, shortness of breath (especially during exercise), frequent respiratory infections, heart palpitations, and poor growth in children. If left untreated, a significant ASD can lead to serious complications over time, including right heart enlargement, pulmonary hypertension, atrial arrhythmias (such as atrial fibrillation or flutter), heart failure, and in rare cases, paradoxical embolism leading to stroke. Treatment depends on the size and type of the defect and the presence of symptoms. Small ASDs may close spontaneously during childhood and require only monitoring. Larger or hemodynamically significant defects typically require closure, which can be achieved through percutaneous transcatheter device closure (for suitable secundum-type defects) or open-heart surgical repair. Early intervention generally carries an excellent prognosis. Patients with repaired ASDs usually have a normal or near-normal life expectancy, though long-term follow-up is recommended to monitor for arrhythmias or residual shunting.
Also known as:
Clinical phenotype terms— hover any for plain English:
Variable
Can be inherited in different ways depending on the underlying gene
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
10 eventsMilton S. Hershey Medical Center — NA
Massachusetts General Hospital — PHASE4
The University of Texas Health Science Center, Houston — NA
New York State Institute for Basic Research — NA
Dartmouth-Hitchcock Medical Center — NA
University of Pittsburgh — NA
University of South Carolina — NA
University of California, Davis — NA
Karuna Therapeutics, Inc., a Bristol Myers Squibb company — PHASE3
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
1 availableDEXMEDETOMIDINE HYDROCHLORIDE
Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer dexmedetomidine hydrochloride by continuous infusion not to exceed …
Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer dexmedetomidine hydrochloride by continuous infusion not to exceed 24 hours.
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
1 resourcesTravel Grants
No travel grants are currently matched to Interatrial communication.
Community
No community posts yet. Be the first to share your experience with Interatrial communication.
Start the conversation →Latest news about Interatrial communication
Disease timeline:
New recruiting trial: Russian Registry of Endovascular Closure of PFO
A new clinical trial is recruiting patients for Interatrial communication
New recruiting trial: Establishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale
A new clinical trial is recruiting patients for Interatrial communication
New recruiting trial: A Comparison of Biodegradable and Metal Occluders in Patients With PFO and Migraine
A new clinical trial is recruiting patients for Interatrial communication
New recruiting trial: Standardized Goal-Directed vs. Self-Directed Valsalva Maneuver for the Assessment of Patent Foramen Ovale
A new clinical trial is recruiting patients for Interatrial communication
New recruiting trial: SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation
A new clinical trial is recruiting patients for Interatrial communication
New recruiting trial: CeraFlex PFO Closure System PMCF Study
A new clinical trial is recruiting patients for Interatrial communication
New recruiting trial: Swartz Sheath With Angioplasty Guidewire-Assisted Technique for Patent Foramen Ovale Closure (STAGE-PFO)
A new clinical trial is recruiting patients for Interatrial communication
New recruiting trial: Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study
A new clinical trial is recruiting patients for Interatrial communication
New recruiting trial: Cerebral Microembolization Associated With PFO Closure
A new clinical trial is recruiting patients for Interatrial communication
New recruiting trial: Efficacy of Three Dimensional Transesophageal Echocardiography for Percutaneous Device Closure in Atrial Septal Defect
A new clinical trial is recruiting patients for Interatrial communication
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Interatrial communication
What is Interatrial communication?
Interatrial communication, commonly known as atrial septal defect (ASD), is a congenital heart defect characterized by an abnormal opening in the septum (wall) that separates the two upper chambers (atria) of the heart. This opening allows oxygen-rich blood from the left atrium to mix with oxygen-poor blood in the right atrium, resulting in a left-to-right shunt that increases blood flow to the lungs. There are several types of ASD, including ostium secundum (the most common, located in the central portion of the septum), ostium primum (located in the lower part of the septum, often associated
Are there clinical trials for Interatrial communication?
Yes — 7 recruiting clinical trials are currently listed for Interatrial communication on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Interatrial communication?
25 specialists and care centers treating Interatrial communication are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.